These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 30979737

  • 41. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, Normant E, Debiec-Rychter M, Schöffski P.
    Clin Cancer Res; 2011 Sep 01; 17(17):5604-14. PubMed ID: 21737509
    [Abstract] [Full Text] [Related]

  • 42. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
    Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P.
    Clin Cancer Res; 2009 Sep 15; 15(18):5910-6. PubMed ID: 19723647
    [Abstract] [Full Text] [Related]

  • 43. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 15; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 44. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 21; 86(43):3064-7. PubMed ID: 17288838
    [Abstract] [Full Text] [Related]

  • 45. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.
    Digestion; 2013 Nov 21; 87(1):47-52. PubMed ID: 23343969
    [Abstract] [Full Text] [Related]

  • 46. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A.
    Eur J Surg Oncol; 2009 Jul 21; 35(7):739-45. PubMed ID: 19110398
    [Abstract] [Full Text] [Related]

  • 47. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
    Matsumoto K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kawai H, Kondo S, Yamao K.
    Jpn J Clin Oncol; 2011 Jan 21; 41(1):57-62. PubMed ID: 20858619
    [Abstract] [Full Text] [Related]

  • 48. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.
    Chi P, Qin LX, Camacho N, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD.
    Clin Cancer Res; 2022 Apr 14; 28(8):1507-1517. PubMed ID: 35110417
    [Abstract] [Full Text] [Related]

  • 49. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
    Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD.
    JAMA Oncol; 2021 Sep 01; 7(9):1343-1350. PubMed ID: 34236401
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
    Li CF, Fang FM, Chen YY, Liu TT, Chan TC, Yu SC, Chen LT, Huang HY.
    Clin Cancer Res; 2017 Aug 15; 23(16):4908-4918. PubMed ID: 28442505
    [Abstract] [Full Text] [Related]

  • 52. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF, Perry CM.
    Drugs; 2003 Aug 15; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [Abstract] [Full Text] [Related]

  • 53. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J.
    Oncologist; 2019 May 15; 24(5):680-687. PubMed ID: 30126859
    [Abstract] [Full Text] [Related]

  • 54. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
    Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, Fumagalli E, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiering C, Le Cesne A.
    Oncol Res Treat; 2019 May 15; 42(12):629-635. PubMed ID: 31550719
    [Abstract] [Full Text] [Related]

  • 55. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M, Deutsch JM.
    Curr Clin Pharmacol; 2015 May 15; 10(4):311-20. PubMed ID: 26548908
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
    Poole CD, Connolly MP, Chang J, Currie CJ.
    Gastric Cancer; 2015 Jul 15; 18(3):627-34. PubMed ID: 24957256
    [Abstract] [Full Text] [Related]

  • 58. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
    Yoo C, Ryu MH, Nam BH, Ryoo BY, Demetri GD, Kang YK.
    Eur J Cancer; 2016 Jan 15; 52():201-8. PubMed ID: 26699729
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.
    Health Technol Assess; 2005 Jul 15; 9(25):1-142. PubMed ID: 15985189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.